Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-beta-hydroxyepiandrosterone is an endogenous steroid metabolite classified as an androgen, estrogen, and neurosteroid. It is produced in the body from dehydroepiandrosterone (DHEA) and epiandrosterone. This compound has been studied for its neuroprotective effects and may mediate some of the neuroprotective actions attributed to DHEA. Mechanistically, it acts as a highly potent antagonist of the G protein-coupled estrogen receptor (GPER), with high affinity (<1 nM). It can also bind to estrogen receptor beta (ERβ) and exhibits anti-inflammatory properties[5][8]. In supplement contexts, it has been used for weight loss, athletic performance enhancement, sexual health issues, and other purposes; however, there is no robust scientific evidence supporting these uses. The substance is considered possibly unsafe when taken orally due to risks such as infertility, behavioral changes, hair loss, breast development in men, liver damage, and heart disease[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-beta-hydroxyepiandrosterone.